/AXLA
AXLA Stock - Axcella Health Inc.
Healthcare|BiotechnologyNASDAQ
$4.58+0.00%
+$0.00 (+0.00%) • Jan 16
77
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.50
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.97
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+1210.0%upside
Target: $60.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for AXLA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.53 – $4.63
TARGET (TP)$60.00
STOP LOSS$4.21
RISK/REWARD1:149.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.57
52W High$4.58
52W Low$0.36
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-72,799,000 | $-61,846,000 | $-53,836,000 | $-57,439,000 | $-33,896,000 |
| Net Income | $-81,186,000 | $-67,118,000 | $-58,809,000 | $-59,973,000 | $-36,069,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.27 | $-1.76 | $-1.85 | $-3.61 | $-2.18 |
Company Overview
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
AXLABeat Rate
56%
Last 16 quarters
Avg Surprise
+2.8%
EPS vs Estimate
Beats / Misses
9/5
2 met exactly
Latest EPS
$-1.25
Q3 2023
EPS Surprise History
Q4 21
+8.9%
$-10.25vs$-11.25
Q4 21
No data
Q2 22
-21.1%
$-11.50vs$-9.50
Q3 22
-11.1%
$-10.00vs$-9.00
Q4 22
+8.1%
$-8.50vs$-9.25
Q1 23
-48.8%
$-0.45vs$-0.30
Q2 23
+75.0%
$-1.25vs$-5.00
Q3 23
0.0%
$-1.25vs$-1.25
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2024 | Aug 1, 2024 | — | — | — | — |
Q2 2024 | May 2, 2024 | $-1.25 | — | — | — |
Q4 2023 | Nov 21, 2023 | $-1.25 | — | — | — |
Q3 2023 | Aug 3, 2023 | $-1.25 | $-1.25 | 0.0% | = MET |
Q2 2023 | May 4, 2023 | $-5.00 | $-1.25 | +75.0% | ✓ BEAT |
Q1 2023 | Mar 23, 2023 | $-0.30 | $-0.45 | -48.8% | ✗ MISS |
Q4 2022 | Nov 1, 2022 | $-9.25 | $-8.50 | +8.1% | ✓ BEAT |
Q3 2022 | Aug 12, 2022 | $-9.00 | $-10.00 | -11.1% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-9.50 | $-11.50 | -21.1% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | — | $-0.46 | — | — |
Q4 2021 | Nov 10, 2021 | $-11.25 | $-10.25 | +8.9% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | $-10.50 | $-10.50 | 0.0% | = MET |
Q2 2021 | May 6, 2021 | $-10.50 | $-10.00 | +4.8% | ✓ BEAT |
Q1 2021 | Mar 17, 2021 | $-9.00 | $-10.00 | -11.1% | ✗ MISS |
Q4 2020 | Nov 12, 2020 | $-9.50 | $-8.50 | +10.5% | ✓ BEAT |
Q3 2020 | Aug 5, 2020 | $-13.00 | $-12.00 | +7.7% | ✓ BEAT |
Q2 2020 | May 11, 2020 | $-23.00 | $-16.25 | +29.3% | ✓ BEAT |
Q1 2020 | Mar 23, 2020 | $-23.25 | $-17.00 | +26.9% | ✓ BEAT |
Q4 2019 | Nov 12, 2019 | $-19.50 | $-18.75 | +3.8% | ✓ BEAT |
Q3 2019 | Aug 12, 2019 | $-17.25 | $-23.75 | -37.7% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about AXLA
What is AXLA's current stock price?
Axcella Health Inc. (AXLA) is currently trading at $4.58 per share. The stock has moved +0.00% today.
What is the analyst price target for AXLA?
The average analyst price target for AXLA is $60.00, based on 1 analyst.
What sector is Axcella Health Inc. in?
Axcella Health Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is AXLA's market cap?
Axcella Health Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does AXLA pay dividends?
No, Axcella Health Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMTI
Applied Molecular Transport Inc.
$0.26
Mkt Cap: $0.0B
CYAD
Celyad Oncology S.A.
$0.47
Mkt Cap: $0.0B
GLS
Gelesis Holdings, Inc.
$0.16
Mkt Cap: $0.0B
HURA
TuHURA Biosciences, Inc.
$0.82
Mkt Cap: $0.0B
KRRO
Korro Bio, Inc.
$7.88
Mkt Cap: $0.1B
NTBL
Notable Labs, Ltd.
$0.25
Mkt Cap: $0.0B
OBSV
ObsEva S.A.
$0.10
Mkt Cap: $0.0B
REUN
Reunion Neuroscience Inc.
$1.12
Mkt Cap: $0.0B
SCPX
Scorpius Holdings, Inc.
$0.00
Mkt Cap: $0.0B
SQZB
SQZ Biotechnologies Company
$0.02
Mkt Cap: $0.0B
Explore stocks similar to AXLA for comparison